Tobramycin pharmacokinetic and pharmacodynamic targets in people with cystic fibrosis
Kiera H Harwood, Sarah Bannister, Stephen Duffull, April Martinez, Sarath Ranganathan, Shivanthan Shanthikumar, Amanda Gwee · 2026
Read Tobramycin pharmacokinetic and pharmacodynamic targets in people with cystic fibrosis by Kiera H Harwood, Sarah Bannister, Stephen Duffull, April Martinez, Sarath Ranganathan, Shivanthan Shanthikumar, Amanda Gwee (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13519771.txt.
Description
Kiera H Harwood leads a seven-author review in 2026 on how much intravenous tobramycin people with cystic fibrosis should receive. The antibiotic is first-line against Pseudomonas lung infections, and higher exposure kills bacteria better, while excess exposure damages kidneys and hearing. Clinicians disagree on which concentration target to chase.
Searching four databases yielded 26 eligible studies. Peak concentration and total daily exposure both tracked with lung function gains, with total exposure the steadier predictor. Trough levels and total exposure tracked with toxicity. Current peak and trough targets still look appropriate, the reviewers conclude, and exposure-guided dosing targeting a defined daily range looks promising. Evidence quality was mostly poor, so better trials are needed.
Catalog record
| CREATOR | Kiera H Harwood, Sarah Bannister, Stephen Duffull, April Martinez, Sarath Ranganathan, Shivanthan Shanthikumar, Amanda Gwee |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40349 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |